Adjusted mortality in BAME compared with white patients undergoing PCI during COVID-19 period compared with pre-COVID-19 period
| COVID-19 period | Reference | Adjusted OR (95% CI)* |
| Adjusted in-hospital mortality | ||
| February 2020 (n=9996) | Pre-COVID-19 period | 0.77 (0.46 to 1.28) |
| March 2020 (n=9088) | Pre-COVID-19 period | 1.11 (0.26 to 4.63) |
| April 2020 (n=8206) | Pre-COVID-19 period | 1.44 (0.24 to 8.60) |
| May 2020 (n=7292) | Pre-COVID-19 period | 3.87 (0.55 to 12.98) |
| Overall mortality 2020 (n=34 582) | Pre-COVID-19 period | 1.28 (0.70 to 2.32) |
| Adjusted 7-day mortality | ||
| February 2020 (n=9996) | Pre-COVID-19 period | 1.05 (0.27 to 3.10) |
| March 2020 (n=9878) | Pre-COVID-19 period | 1.82 (0.45 to 7.37) |
| April 2020 (n=8206) | Pre-COVID-19 period | 1.62 (0.14 to 3.99) |
| May 2020 (n=7292) | Pre-COVID-19 period | 3.59 (0.49 to 8.31) |
| Overall mortality 2020 (n=34 582) | Pre-COVID-19 period | 1.40 (0.68 to 2.86) |
*Adjusted for age, gender, ethnicity, heart rate, blood pressure, body mass index, serum creatinine level, family history of coronary heart diseases, left ventricle systolic dysfunction, history of heart failure, prior percutaneous coronary intervention (PCI), history of diabetes mellitus, hypercholesterolaemia, history of angina, history of myocardial infarction, history of cerebrovascular accident, history of peripheral vascular disease, hypertension, smoking, asthma/COPD, admission under cardiology, prescription of low molecular weight heparin, warfarin, unfraction heparin, GP 2b/3a inhibitor, furosemide, ACE inhibitor/angiotensin receptor blockers, aspirin, P2Y12 inhibitor, cardiogenic shock, arterial blood gas, Glasgow coma scale, mechanical ventilation, lesions attempted, vessel attempted, multivessel PCI, number of stents inotropic support, intravascular ultrasound, fractional flow reserve, optical coherence tomography, intra-aortic balloon pump and impella use on imputed data.
BAME, black, Asian and minority ethnic; COPD, chronic obstructive pulmonary disease; P2Y12, purinergic receptor inhibitor.